Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859628 | 0.94 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL9913932 | 0.94 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL14990786 | 0.93 | PDE5A (0.45) | PDE5AGUCY1A1GUCY1B1 | |
| Acetic Acid SCHEMBL16244728 | 0.92 | GUCY1A1 (0.42) | PDE5AGUCY1A1GUCY1B1 | |
| Formic Acid SCHEMBL30884591 | 0.91 | PDE5A (0.45) | PDE5AGUCY1A1GUCY1B1 | |
| Acetic Acid SCHEMBL16244815 | 0.90 | PTGDR2 (0.40) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174635 | 0.87 | PDE5A (0.48) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| Hydrochloric Acid SCHEMBL29219152 | 0.86 | PDE5A (0.47) | PDE5AGUCY1A1GUCY1B1 | |
| Acetic Acid SCHEMBL19205296 | 0.86 | PDE5A (0.36) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| SCHEMBL18672347 | 0.86 | PDE5A (0.51) | PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | TORRENT PHARMACEUTICALS LTD (IN) | 2026-03-05 | — | — | US | disclosed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | disclosed |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2022-09-13 | — | — | US | disclosed |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-10736896-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | ADVERIO PHARMA GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180263981-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2018-09-20 | — | — | US | disclosed |
| US-9993476-B2 | Substituted 5-flouro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20170273977-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140038956-A1 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20130338137-A1 | Substituted annellated pyrimidines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-20130237551-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8420656-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2576548-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | Bayer Intellectual Property GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | GUCY1B1, GUCY1A2, GUCY1B2 | PDE5A 15/4885GUCY1A1 4/4885GUCY1B1 1/4885 |
| US-20170273977-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-20140038956-A1 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). | PDE5A, PDE3A, PDE2A | PDE5A 1/4885GUCY1A1 6/4885GUCY1B1 10/4885 |
| US-20130338137-A1 | Substituted annellated pyrimidines and use thereof | TYMS, TYMP, NUDT1 | PDE5A 1606/4885GUCY1A1 2669/4885GUCY1B1 2119/4885 |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-10736896-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-20180263981-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-20130158028-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | PDE5A, GUCY1A1, PDE2A | PDE5A 1/4885GUCY1A1 2/4885GUCY1B1 8/4885 |
| US-20200397785-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | PDE5A 152/4885GUCY1A1 1153/4885GUCY1B1 656/4885 |
| US-20130237551-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | PDE5A, PDE3A, PDE2A | PDE5A 1/4885GUCY1A1 6/4885GUCY1B1 10/4885 |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | PDE3B, PDE5A, PDE2A | PDE5A 2/4885GUCY1A1 9/4885GUCY1B1 26/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.